June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Detection of anti-ranibizumab antibodies among exudative AMD patients
Author Affiliations & Notes
  • Nicolas Leveziel
    Ophthalmology, Poitiers University Hospital, Poitiers, France
    Ophthalmology, Creteil Eye University, Creteil, France
  • Thibaut Pelat
    DBAT/Biotechnologies des anticorps, Centre de Recherche du Service de Santé des Armées, La Tronche, France
  • Hervé Watier
    Pilot centre for Therapeutic Antibody Monitoring, Université François-Rabelais de Tours, CNRS UMR 7292, CHRU de Tours, Tours, France
  • Philippe Thullier
    DBAT/Biotechnologies des anticorps, Centre de Recherche du Service de Santé des Armées, La Tronche, France
  • Eric Souied
    Ophthalmology, Creteil Eye University, Creteil, France
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3170. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicolas Leveziel, Thibaut Pelat, Hervé Watier, Philippe Thullier, Eric Souied; Detection of anti-ranibizumab antibodies among exudative AMD patients. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3170.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The prognosis of the exudative form of age-related macular degeneration has been largely improved with the use intravitreal injections of anti-VEGF. However, more than 10% of patients do not respond completely to the treatment, likely due to genetic predispositions, particular clinical forms or to tachyphylaxis. The aim of this study was to detect immune response induced by intravitreal injections of ranibizumab in exudative AMD patients.

Methods: Blood samples were collected from exudative AMD patients with previous or no history of intravitreal injections of Ranibizumab in a same clinical setting. Specific immunization was proved using a combination of ELISA. A first ELISA was used to detect antibodies directed against the variable regions of ranibizumab. A second ELISA with abciximab (Reopro®, Elli Lilly) was used as a control antigen to detect false positive results, because abciximab shares with ranibizumab same constant regions.

Results: Among 91 patients (28 men and 63 women, mean age 79) included in this study, 46 received more than 10 IVTs, 36 had received 10 IVTs or less and 9 were treatment naïve. Specific anti-ranibizumab IgGs were detected in 17.1% of patients previously treated with ranibizumab. Among patients with 10 or less previous IVT, immunization against Ranibizumab was detected in 4 of 36 patients (11.1%) whereas immunization was observed in 10 of 46 patients (21.7%) with more than 10 previous IVT (p=0.20). No immunization was detected among naive patients.

Conclusions: These results suggest that immunization against ranibizumab could be commonly observed and may perhaps influence the clinical outcome of treatment. No correlation was observed between the level of immunization and ocular inflammation in the present study. Further clinical studies are needed to investigate the relationship between specific immunization to anti-VEGFs and resistance to these treatments.

Keywords: 412 age-related macular degeneration • 561 injection • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×